Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics (DE:1S90)
FRANKFURT:1S90
Total Valuation
Seres Therapeutics has a market cap or net worth of €78.01M. The enterprise value is €122.10M.
Market Cap€78.01M
Enterprise Value€122.10M
Share Statistics
Seres Therapeutics has 9,586,298 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding9,586,298
Owned by Insiders2.01%
Owned by Institutions14.02%
Financial Efficiency
Seres Therapeutics’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is -72.70%.
Return on Equity (ROE)0.13
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)-72.70%
Return on Capital Employed (ROCE)-0.79
Revenue Per Employee7.66K
Profits Per Employee55.30K
Employee Count103
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Seres Therapeutics is ―. Seres Therapeutics’s PEG ratio is -0.22.
PE Ratio―
PS Ratio167.07
PB Ratio2.98
Price to Fair Value2.98
Price to FCF152.39
Price to Operating Cash Flow74.43
PEG Ratio-0.22
Income Statement
In the last 12 months, Seres Therapeutics had revenue of 789.00K and earned 5.70M in profits. Earnings per share was 0.64.
Revenue789.00K
Gross Profit-3.34M
Operating Income-93.97M
Pretax Income5.70M
Net Income5.70M
EBITDA-89.84M
Earnings Per Share (EPS)0.64
Cash Flow
In the last 12 months, operating cash flow was 1.12M and capital expenditures -252.00K, giving a free cash flow of 865.00K billion.
Operating Cash Flow1.12M
Free Cash Flow865.00K
Free Cash Flow per Share0.09
Dividends & Yields
Seres Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-2.69
52-Week Price Change-44.39%
50-Day Moving Average10.29
200-Day Moving Average11.28
Relative Strength Index (RSI)34.33
Average Volume (3m)0.00
Important Dates
Seres Therapeutics upcoming earnings date is May 13, 2026, Before Open (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
Seres Therapeutics as a current ratio of 2.56, with Debt / Equity ratio of 187.63%
Current Ratio2.56
Quick Ratio2.56
Debt to Market Cap0.08
Net Debt to EBITDA-0.41
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Seres Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Seres Therapeutics EV to EBITDA ratio is -1.88, with an EV/FCF ratio of 195.40.
EV to Sales214.22
EV to EBITDA-1.88
EV to Free Cash Flow195.40
EV to Operating Cash Flow151.32
Balance Sheet
Seres Therapeutics has €45.77M in cash and marketable securities with €82.97M in debt, giving a net cash position of -€37.20M billion.
Cash & Marketable Securities€45.77M
Total Debt€82.97M
Net Cash-€37.20M
Net Cash Per Share-€3.88
Tangible Book Value Per Share€4.99
Margins
Gross margin is -423.83%, with operating margin of -11910.14%, and net profit margin of 721.93%.
Gross Margin-423.83%
Operating Margin-11910.14%
Pretax Margin721.93%
Net Profit Margin721.93%
EBITDA Margin-11386.31%
EBIT Margin-11910.14%
Analyst Forecast
The average price target for Seres Therapeutics is €18.34, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€18.34
Price Target Upside145.88% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―